Post by Deleted on Mar 9, 2018 0:35:03 GMT
This came from the N R on PGNX today:
Over the last few years, the oncology division of the FDA has approved many drugs well ahead of their PDUFA dates, and their doing so in this case wouldn't be surprising, given the lack of treatment options for patients with late-stage pheochromocytoma and paraganglioma.
The key statement here is:
"FDA has approved many drugs well ahead of their PDUFA dates"
C L
